大鼠口服芍苓消银片后血液中芍药苷、落新妇苷、迷迭香酸、异嗪皮啶、甘草苷的药物动力学研究

Pharmacokinetic study on peoniflorin,astilbin,rasmarinci acid,isofraxidin and liquiritin in rat blood after oral administration of Shaolin Xiaoyin tablets

芍药苷、落新妇苷、迷迭香酸、异嗪皮啶和甘草苷为芍苓消银片中主要成分，为给其后期剂型及临床用药方案设计奠定基础，该文建立了这5种成分血药浓度含量测定方法并进行大鼠体内药物动力学的研究。血药浓度测定采用HPLC测定，菲罗门C18色谱柱（4．6mm×250mm，5μm），甲醇-乙腈-0．05％甲酸梯度洗脱，流速0．8mL·min-1，检测波长275nm。样品处理采用固相萃取法。大鼠灌胃芍苓消银片浸膏后分别于不同时间采血，测定血药浓度。实验结果显示5种成分可基线分离，芍药苷、异嗪皮啶、落新妇苷、迷迭香酸和甘草苷分别在2．48—248，0．2136～21．36，0．531—53．1，0．704～70．4，0．253～25．3mg·L。线形关系良好。5种成分均可吸收入血，均为快速吸收、快速消除的模式。该文建立的方法快速、准确，可用于含同类成分的制剂的体内分析，芍苓消银片中主要成分吸收消除较快，适合制备成缓控释制剂，普通制剂可能需要1d服药4～6次。

To establish a method for the determination of astilbin, peoniflorin, rasmarinci acid, isofraxidin and liquiritin con- tained in Shaolin Xiaoyin tablets, in order to lay a foundation for designing late-stage dosage forms and clinical medication schemes. In this paper, efforts were made to establish a method for the determination of the blood concentration of the five components and study the in vivo pharmacokinetics in rats. The blood concentration was determined by HPLC. Phenomenex Cls column （4. 6 mm ×250 mm, 5 μm） was adopted and eluted with methanol-acetonitrile-0. 05% formic acid, the flow rate was 0. 8 mL·min-1 , and the wavelength was 275 nm. The samples were processed by the solid phase extraction method. After oral administration of Shaoling Xiaoyin tablets, the rat bloods were collected at different time points to determine the blood concentrations. The experimental results showed that the baseline separation could be adopted for the five components, and astilbin, peoniflorin, rasmarinci acid, isofraxidin and liquiritin showed good linear relations within ranges of 2. 48-248, 0. 213 6-21.36, 0. 531-53.1,0. 704-70. 4, 0. 253-25.3 mg·L-1. All the five components could be absorbed in blood and excreted quickly. The method established in this paper is rapid and accurate, and could be used for in vivo analysis on preparations containing similar components. The main components in Shaoling Xiaoyin tablets could be ab- sorbed and excreted quickly, and thus suitable to be made into sustained release tablets. Common preparations are required to be taken for 4-6 times a day.